Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) Invested Capital (2021 - 2025)

Historic Invested Capital for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $247.7 million.

  • ARS Pharmaceuticals' Invested Capital rose 2322.49% to $247.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $247.7 million, marking a year-over-year increase of 2322.49%. This contributed to the annual value of $256.8 million for FY2024, which is 1128.36% up from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Invested Capital of $247.7 million as of Q3 2025, which was up 2322.49% from $192.3 million recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' Invested Capital ranged from a high of $369.0 million in Q1 2021 and a low of -$31.3 million during Q4 2021
  • In the last 5 years, ARS Pharmaceuticals' Invested Capital had a median value of $248.6 million in 2023 and averaged $246.1 million.
  • The largest annual percentage gain for ARS Pharmaceuticals' Invested Capital in the last 5 years was 97270.46% (2022), contrasted with its biggest fall of 2054.33% (2022).
  • ARS Pharmaceuticals' Invested Capital (Quarter) stood at -$31.3 million in 2021, then surged by 972.7% to $272.9 million in 2022, then fell by 15.44% to $230.8 million in 2023, then increased by 11.28% to $256.8 million in 2024, then fell by 3.56% to $247.7 million in 2025.
  • Its last three reported values are $247.7 million in Q3 2025, $192.3 million for Q2 2025, and $229.0 million during Q1 2025.